Abstract: Optimistic concurrency may be implemented for multiple writers to a database. Writes to a database from different writers may succeed unless a conflict is detected at the data store for the database. For detected conflicts, a request to resolve the conflict between writes may be submitted to a primary writer, which may determine and provide a resolution of the conflict to the conflicting writers. The data store may then be updated to commit the selected write identified by the resolution of the conflict.

Abstract: Aspects of the present disclosure relate to generating an engagement model to predict actions that may have a high probability of maintaining user engagement in-application or causing a user to reengage with the application. To generate the engagement model, an approach has been developed which incorporates features analysis of the application and application users. Users may be grouped based on similar features that are used to generate machine learning engagement models. The output of an engagement model may be a prediction on whether a user will continue to engage with an application. The prediction may be provided to a reengagement model which may output prompts to help increase user engagement with the application. The prompts may be based on an understanding of application users and their preferences.

Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat. The dermal fibrotic disorder is acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, peyronie's disease, dupuytren's contracture, or adhesive capsulitis.

Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat.